Hyperglycemia triggers HIPK2 protein degradation

Area of Science:

• Molecular Biology
• Cancer Research
• Endocrinology

Background:

• Homeodomain interacting protein kinase-2 (HIPK2) is crucial for tumor suppression and apoptosis induction via p53.
• HIPK2 inhibition in cancer cells promotes chemoresistance and progression.
• Hyperglycemia impairs p53 apoptotic function by reducing its phosphorylation.

Purpose of the Study:

• To investigate if hyperglycemia targets HIPK2 protein stability.
• To elucidate the mechanisms underlying high glucose-induced HIPK2 downregulation.

Main Methods:

• Assessed HIPK2 protein levels under high glucose conditions.
• Utilized proteasome and protein phosphatase inhibitors (MG132, Calyculin A, Okadaic Acid).
• Investigated the role of protein phosphatase 2A (PP2A) and hypoxia-inducible factor-1 (HIF-1) in HIPK2 degradation.

Main Results:

• High glucose significantly reduced HIPK2 protein levels, diminishing its pro-apoptotic activity.
• Proteasome and phosphatase inhibitors rescued HG-induced HIPK2 degradation.
• PP2A activation promoted HIPK2 degradation, while PP2A silencing prevented it.
• HIF-1 activity and Siah2 ubiquitin ligase were implicated in HG-triggered HIPK2 proteasomal degradation.

Conclusions:

• Hyperglycemia downregulates HIPK2 protein levels through a cascade involving PP2A and HIF-1.
• This HIPK2 downregulation impairs p53-mediated apoptosis, contributing to therapy resistance.
• Establishes a novel link between diabetes/obesity and reduced efficacy of cancer therapies.